PUBLISHER: The Business Research Company | PRODUCT CODE: 1686454
PUBLISHER: The Business Research Company | PRODUCT CODE: 1686454
A gastrointestinal stromal tumor (GIST) is a rare type of non-epithelial tumor that originates in the gastrointestinal (GI) tract. These tumors most commonly develop in the stomach or the small intestine, although they can occur anywhere along the GI tract, from the esophagus to the rectum.
The main treatment modalities for gastrointestinal stromal tumors include chemotherapy, targeted therapy, and others. Chemotherapy is a medical treatment that utilizes potent drugs to target and eliminate rapidly dividing cells in the body, including cancer cells. It is prescribed for various indications such as those affecting the stomach, small intestine, and other parts of the GI tract. Different end-users, including hospitals, clinics, specialized cancer treatment centers, and others, may administer chemotherapy as part of the treatment regimen.
The gastrointestinal stromal tumor market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal stromal tumor market statistics, including gastrointestinal stromal tumor industry global market size, regional shares, competitors with a gastrointestinal stromal tumor market share, detailed gastrointestinal stromal tumor market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal stromal tumor industry. This gastrointestinal stromal tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increased awareness and early diagnosis, emergence of targeted therapies, enhanced surgical techniques, development of personalized medicine, improvements in supportive care.
The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to continued research and drug development, rise in patient-centric healthcare, integration of precision medicine in clinical practice, increasing access to targeted therapies, expanding genomic profiling capabilities. Major trends in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, exploration of combination therapies.
The increasing incidence of stomach cancer is expected to drive the growth of the gastrointestinal stromal tumor market in the future. Stomach cancer is characterized by the uncontrolled proliferation of malignant cells in the stomach lining. While gastrointestinal stromal tumors (GISTs) can develop in the stomach, they are different from stomach cancer. Patients with GISTs have been observed to have a heightened risk of developing other cancers, including small bowel adenocarcinoma, particularly when two distinct tumors collide and merge. For example, the American Cancer Society, a U.S.-based professional organization, projected in January 2024 that approximately 26,890 new cases of stomach cancer and 10,880 deaths will occur in the U.S. in 2024, representing 1.5% of all new cancer diagnoses. Hence, the rising incidence of stomach cancer is propelling the growth of the gastrointestinal stromal tumor market.
The growing demand for precision medicine is anticipated to further advance the gastrointestinal stromal tumor market in the coming years. Precision medicine refers to a tailored approach to medical treatment that customizes healthcare decisions, interventions, and therapies based on individual patient characteristics, such as genetics and lifestyle factors. In the context of gastrointestinal stromal tumors, precision medicine involves molecular profiling to detect specific mutations, which directs targeted therapies like imatinib, enhancing treatment effectiveness while reducing side effects through personalized interventions. For instance, a report by the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, indicated in February 2023 that personalized medicines represented 35% of newly approved new molecular entities (NMEs) in 2021, and with 12 new approvals in 2022, they have consistently accounted for at least a quarter of new drug approvals over the past eight years, marking a significant rise from less than 10% a decade ago. Therefore, the growing demand for precision medicine is driving the expansion of the gastrointestinal stromal tumor market.
Major companies in the gastrointestinal stromal tumor market are developing innovative drugs like QINLOCK (Ripretinib) to cater to larger customer bases, boost sales, and enhance revenue. QINLOCK (Ripretinib) is a prescription medication used for the treatment of advanced gastrointestinal stromal tumors (GIST). For example, in January 2024, the U.S. Food and Drug Administration (FDA), a federal agency, reported that the Center for Drug Evaluation and Research (CDER) approved 37 novel drugs in 2022, which increased to 55 drugs in 2023. CDER noted that 20 of the 55 novel drugs (36%) approved in 2023 were classified as first-in-class.
In June 2022, Immatics N.V., a Germany-based biotechnology company, formed a partnership with Bristol Myers Squibb to develop gamma delta allogeneic cell therapy programs. This collaboration aims to create advanced cancer immunotherapies with the potential to enhance the treatment of various cancers, including gastrointestinal stromal tumors (GISTs). Bristol Myers Squibb, a US-based pharmaceutical company, is actively involved in developing treatments related to GISTs.
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the gastrointestinal stromal tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The gastrointestinal stromal tumor market includes revenues earned by entities by providing services such as diagnostic services, pathology services, pathology services, and pathology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal stromal tumor market also includes sales of targeted therapy, chemotherapy, radiation therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastrointestinal Stromal Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastrointestinal stromal tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for gastrointestinal stromal tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastrointestinal stromal tumor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.